Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/the-cost-effectiveness-of-statin-therapies-in-spain-in-2010-after-the-vXXwehBIxs
References (89)
-
A. Dart, G. Jerums, G. Nicholson, M. d’Emden, I. Hamilton‐Craig, G. Tallis, J. Best, M. West, D. Sullivan, P. Bracs, D. Black (1997)
A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients witb hypercholesterolemiaAmerican Journal of Cardiology, 80
-
H. Langtry, A. Markham (1999)
FluvastatinDrugs, 57
-
H.D. Langtry, A. Markham (1999)
Fluvastatin: a review of its use in lipid disordersDrugs, 57
-
U.M. Henwood, R.C. Heel (1988)
Lovastatin. A preliminary review of its pharmaco-dynamic properties and therapeutic use in hyperlipidaemiaDrugs, 36
-
S. Lewis, F. Sacks, J. Mitchell, C. East, S. Glasser, Sheren Kell, R. Letterer, M. Limacher, L. Moye, J. Rouleau, M. Pfeffer, E. Braunwald (1998)
Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial.Journal of the American College of Cardiology, 32 1
-
(2010)
Nomenclator, 2010 -
J. Shepherd, S.M. Cobe, I. Ford (1995)
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study GroupN Engl J Med, 333
-
A. Tonkin, P. Alyward, D. Colquhoun, P. Glasziou, P. Harris, D. Hunt, A. Keech, S. MacMahon, P. Magnus, D. Newel, P. Nestel, N. Sharpe, J. Shaw, R. Simes, P. Thompson, A. Thompson, M. West, H. White, S. Simes, W. Hague, S. Caleo, Jane Hall, Andrew Martin, S. Mulray, P. Barter, L. Beilin, R. Collins, J. McNeil, P. Meier, H. Willimott, D. Smithers, P. Wallace, J. Baker, M. Hobbs, D. Sullivan, N. Anderson, G. Hankey, J. Watson, M. Arulchelvam, S. Chup, J. Daly, J. Hanna, A. Leach, M. Lee, J. Loughhead, H. Lundie-Jenkin, J. Morrison, S. Netting, A. Nguyen, H. Pater, R. Philip, G. Pinna, D. Rattos, S. Ryerson, V. Sazhin, R. Walsh, A. Claque, M. Mackie, J. Yallop, K. Boss, M. Shepard, J. Leach, M. Gandy, J. Joughin, J. Seabrook, R. Abraham, J. Allen, F. Bates, I. Beinart, E. Breed, D. Brown, N. Bunyan, D. Calvert, T. Campbell, D. Condon‐Paoloni, B. Conway, L. Coupland, J. Crowe, N. Cunio, B. Cuthbert, N. Cuthbert, S. D'arcy, P. Davidson, B. Dwyer, J. England, C. Friend, G. Fulcher, S. Grant, K. Hellestrand, M. Kava, L. Kritharides, D. McGill, H. McKee, A. Mclean, M. Neaverson, G. Nelson, M. O'Neill, C. Onuma, F. O'Reilly (1998)
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.The New England journal of medicine, 339 19
-
D. Black, R. Bakker-Arkema, T. Heinonen, J. Nawrocki (1998)
D027: Does the presence of either concurrent hypertension or non-insulin-dependent diabetes mellitus affect the efficacy and safety of atorvastatin in patients with hyperlipidemia?American Journal of Hypertension, 11
-
M. Johannesson, M. Johannesson, M. Weinstein (1993)
On the decision rules of cost-effectiveness analysis.Journal of health economics, 12 4
-
I. Zechmeister, P. Radlberger (2008)
Gesundheitsökonomische EvaluationWiener Medizinische Wochenschrift, 159
-
A. Olsson, M. Eriksson, Owe Johnson, T. Kjellström, J. Lanke, M. Larsen, T. Pedersen, M. Tikkanen, O. Wiklund (2003)
A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) study.Clinical therapeutics, 25 1
-
Michael Prisant, M. Downton, L. Watkins, H. Schnaper, R. Bradford, A. Chremos, A. Langendorfer (1996)
Efficacy and tolerability of lovastatin in 459 African-Americans with hypercholesterolemia.The American journal of cardiology, 78 4
-
Matthew Higgins, Stuart Graham (2009)
Balancing Innovation and Access: Patent Challenges Tip the ScalesScience, 326
-
A. Jula, J. Marniemi, R. Huupponen, A. Virtanen, M. Rastas, T. Rönnemaa (2002)
Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial.JAMA, 287 5
-
P. Zweifel, L. Crivelli (1996)
Price regulation of drugs: Lessons from GermanyJournal of Regulatory Economics, 10
-
J. Shepherd, G. Blauw, M. Murphy, E. Bollen, B. Buckley, S. Cobbe, I. Ford, A. Gaw, M. Hyland, J. Jukema, A. Kamper, P. Macfarlane, A. Meinders, J. Norrie, C. Packard, I. Perry, D. Stott, Brian Sweeney, Gillian Twomey, R. Westendorp (2002)
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trialThe Lancet, 360
-
A. Branchi, A. Fiorenza, A. Rovellini, A. Torri, F. Muzio, S. Macor, D. Sommariva (1999)
Lowering effects of four different statins on serum triglyceride levelEuropean Journal of Clinical Pharmacology, 55
-
B. Jacotot, R. Benghozi, P. Pfister, David Holmes (1995)
Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. French Fluvastatin Study Group.The American journal of cardiology, 76 2
-
H. Malhotra, K. Goa (2001)
Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.Drugs, 61 12
-
J. Bentkover, B. Boselli, P. Lambird, K. Shulman, B. Kinosian, T. Jacobson, H. Glick, J. Eisenberg, H. Koffer, M. Willian (1991)
REDUCING HIGH BLOOD CHOLESTEROL LEVELS WITH DRUGS. AUTHORS' REPLYJAMA, 265
-
W.V. Brown, H.E. Bays, D.R. Hassman (2002)
Rosuvastatin Study Group: effectiveness and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trialAm Heart J, 144
-
J.H. Zavoral, B.J. Haggerty, A.G. Winick (1995)
Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. FLUENT Study Group. Fluvastatin Long-Term Extension TrialAm J Cardiol, 76
-
(1997)
Efficacy of atorvastatin in primary hypercholesterolemiaAm J Cardiol, 79
-
L. Ose, M. Davidson, W. Insull, Mei Wu, A. Tate, M. Melino, M. Mercuri, Y. Mitchel, E. Stein, J. Kastelein, R. Scott, D. Hunninghake, S. Campodónico, I. Escobar, M. Stepanavage, H. Schrott (2000)
Lipid‐Altering Efficacy and Safety of Simvastatin 80 mg/Day: Long‐Term Experience in a Large Group of Patients with HypercholesterolemiaClinical Cardiology, 23
-
(1993)
Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemiaAm J Cardiol, 71
-
J. Rindone, D. Hiller, Greg Arriola (1998)
A Comparison of Fluvastatin 40 mg Every Other Day versus 20 mg Every Day in Patients with HypercholesterolemiaPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 18
-
L. García-Rodríguez, E. Massó-González, M. Wallander, S. Johansson (2008)
The safety of rosuvastatin in comparison with other statins in over 100 000 statin users in UK primary carePharmacoepidemiology and Drug Safety, 17
-
B. Boselli (1991)
Reducing High Blood Cholesterol Levels With DrugsJAMA, 265
-
(1997)
Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease. -
Michael Davidson, J. Mckenney, E. Stein, H. Schrott, R. Bakker-Arkema, R. Fayyad, D. Black (1997)
Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.The American journal of cardiology, 79 11
-
T. Pedersen, A. Olsson, O. Faergeman, J. Kjekshus, H. Wedel, Kåre Berg, L. Wilhelmsen, T. Haghfelt, G. Thorgeirsson, K. Pyörälä, T. Miettinen, B. Christophersen, J. Tobert, T. Musliner, T. Cook (1998)
Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)Circulation, 97 15
-
J.D. Banga, B. Jacotot, P. Pfister (1994)
Long-term treatment of hypercholesterolemia with fluvastatin: a 52-week multicenter safety and efficacy study. French-Dutch Fluvastatin Study GroupAm J Med, 96
-
D. Hilleman, J. Phillips, S. Mohiuddin, K. Ryschon, C. Pedersen (1999)
A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.Clinical therapeutics, 21 3
-
J. Benner, T. Smith, D. Klingman, J. Tierce, C. Mullins, N. Pethick, J. O'donnell (2005)
Cost-effectiveness of rosuvastatin compared with other statins from a managed care perspective.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 8 6
-
(2002)
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.Circulation, 106 25
-
G. Giuliani, G. Selke, L. Garattini (1998)
The German experience in reference pricing.Health policy, 44 1
-
R. Bradford, C. Shear, A. Chremos, C. Dujovne, M. Downton, F. Franklin, A. Gould, M. Hesney, J. Higgins, D. Hurley (1991)
Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia.Archives of internal medicine, 151 1
-
(1993)
A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemiaAm J Cardiol, 71
-
R. Bakker-Arkema, J. Best, R. Fayyad, T. Heinonen, A. Marais, J. Nawrocki, D. Black (1997)
A brief review paper of the efficacy and safety of atorvastatin in early clinical trials.Atherosclerosis, 131 1
-
(2006)
El mercado del medicamento en EspañaBoletin de Coyuntura, 11
-
J. Henwood, R. Heel (2012)
LovastatinDrugs, 36
-
J. Kastelein, F. Akdim, E. Stroes, A. Zwinderman, M. Bots, A. Stalenhoef, F. Visseren, E. Sijbrands, M. Trip, E. Stein, D. Gaudet, R. Duivenvoorden, E. Veltri, A. Marais, E. Groot (2008)
Simvastatin with or without ezetimibe in familial hypercholesterolemia.The New England journal of medicine, 358 14
-
M. Koren, Dean Smith, D. Hunninghake, M. Davidson, J. Mckenney, S. Weiss, Robert Henley, P. Tresh, R. McLain, R. Bakker-Arkema, D. Black (1998)
The Cost of Reaching National Cholesterol Education Program (NCEP) Goals in Hypercholesterolaemic PatientsPharmacoEconomics, 14
-
T. Peters, E. Muratti, M. Mehra (1994)
Fluvastatin in primary hypercholesterolemia: efficacy and safety in patients at high risk. An analysis of a clinical trial database.The American journal of medicine, 96 6A
-
C. Blum (1994)
Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.The American journal of cardiology, 73 14
-
L. Ose, M.H. Davidson, E.A. Stein (2000)
Lipid-altering efficacy and safety of simvastatin 80mg/day: long-term experience in a large group of patients with hypercholesterolemia. World Wide Expanded Dose Simvastatin Study GroupClin Cardiol, 23
-
C. Pinto, M. Carrageta, L. Miguel (2005)
Cost-effectiveness of rosuvastatin in the prevention of ischemic heart disease in Portugal.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 11 2
-
B. Jacotot, J. Banga, R. Waite, T. Peters (1995)
Long-term efficacy with fluvastatinas monotherapy and combined with cholestyramine (A 156-week multicenter study)American Journal of Cardiology, 76
-
Yvan Tran, T. Frial, P. Miller (2007)
Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique, 14 2
-
G.D.H. MacLaine, H. Patel (2001)
A cost-effectiveness model of alternative statins to achieve target LDL-C levelsInt J Clin Pract, 55
-
T. Heinonen, E. Stein, S. Weiss, J. Mckenney, M. Davidson, L. Shurzinske, D. Black (1996)
The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized, double-masked study.Clinical therapeutics, 18 5
-
P. Plans-Rubió (2009)
HDL and LDL cholesterol: physiology and clinical significance -
W. Brown, H. Bays, D. Hassman, J. Mckenney, R. Chitra, H. Hutchinson, Elinor Miller (2002)
Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial.American heart journal, 144 6
-
D. Karalis, A. Ross, Ralph Vacari, H. Zarren, R. Scott (2002)
Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease.The American journal of cardiology, 89 6
-
J. Banga, B. Jacotot, P. Pfister, M. Mehra (1994)
Long-term treatment of hypercholesterolemia with fluvastatin: A 52-week multicenter safety and efficacy studyThe American Journal of Medicine, 96
-
T. Peters (1995)
Fluvastatin in severe hypercholesterolemia: analysis of a clinical trial database.The American journal of cardiology, 76 2
-
J. Farmer, L. Washington, Peter Jones, D. Shapiro, A. Gotto, G. Mantell (1992)
Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. The Simvastatin and Lovastatin Multicenter Study Participants.Clinical therapeutics, 14 5
-
Gdh MacLaine, H. Patel (2001)
A COST‐EFFECTIVENESS MODEL OF ALTERNATIVE STATINS TO ACHIEVE TARGET LDL‐CHOLESTEROL LEVELSInternational Journal of Clinical Practice, 55
-
(2008)
Principios activos de mayor consumo en el Sistema Nacional de Salud durante 2007Información Terapéutica del Sistema Nacional de Salud, 32
-
J. Puig-Junoy (2007)
The impact of generic reference pricing interventions in the statin market.Health policy, 84 1
-
G. López-Casasnovas, J. Puig-Junoy (2000)
Review of the literature on reference pricing.Health policy, 54 2
-
J. Nawrocki, S. Weiss, M. Davidson, D. Sprecher, S. Schwartz, P. Lupien, P. Jones, H. Haber, D. Black (1995)
Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor.Arteriosclerosis, thrombosis, and vascular biology, 15 5
-
P. Plan Rubió (2003)
Impacto sobre el sistema sanitario catalán de la aplicación de las recomendaciones del segundo y tercer informes del National Cholesterol Education Program (ATP-II y ATP-III) sobre prevención y control de la hipercolesterolemia en adultosClin Invest Arterioscl, 15
-
A. Keech, R. Collins, S. MacMahon, J. Armitage, A. Lawson, K. Wallendszus, M. Fatemian, E. Kearney, V. Lyon, J. Mindell (1994)
Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study.European heart journal, 15 2
-
B. Jacotot, J.D. Banga, R. Waite (1995)
Long-term efficacy with fluvastatin as monotherapy and combined with cholestyramine (a 156-week multicenter study). French-Dutch Fluvastatin Study GroupAm J Cardiol, 76
-
M.J. Koren, D.G. Smith, D.B. Hunninghake (1998)
The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolemic patients: a comparison of atorvastatin, simvastatin, lovastatin and fluvastatinPharmacoeconomics, 14
-
F. Sacks, M. Pfeffer, L. Moye, J. Rouleau, J. Rutherford, T. Cole, L. Brown, J. Warnica, J. Arnold, C. Wun, B. Davis, E. Braunwald (1996)
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.The New England journal of medicine, 335 14
-
L. Ferder, M. Bertolami, S. Giannini, J. Cortázar, A. Obonarellano, E. Agner, A. Leth, S. Mattila, M. Tikkanen, J. Fruchart, W. Dutz, K. Gunther, A. Gutschker, G. Heineman, K. Moricke, W. Reuter, E. Steinhagenthiessen, M. Krankenhaus, P. Toutouzas, Y. Tai, A. Rubenstein, J. Rull, L. Ose, F. Garmendia, M. Carrageta, J. Martinscorreia, L. Alvarezsala, J. Gimilio, M. Melino, Y. Mitchel, J. Ng, E. Stein (1993)
A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. The Lovastatin Pravastatin Study Group.The American journal of cardiology, 71 10
-
J. Herd, J. Herd, J. Herd, C. Ballantyne, C. Ballantyne, C. Ballantyne, J. Farmer, J. Farmer, J. Farmer, J. Ferguson, James Ferguson, James Ferguson, Peter Jones, Peter Jones, Peter Jones, M. West, M. West, M. West, K. Gould, K. Gould, K. Gould, A. Gotto, A. Gotto, A. Gotto (1997)
Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]).The American journal of cardiology, 80 3
-
J. Shepherd, S. Cobbe, I. Ford, C. Isles, A. Lorimer, P. Macfarlane, J. Mckillop, C. Packard (1995)
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemiaThe New England Journal of Medicine, 333
-
C. Newman, J. Tsai, M. Szarek, Don Luo, E. Gibson (2006)
Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients.The American journal of cardiology, 97 1
-
(2001)
Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel-III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (ATP-III)JAMA, 285
-
A. Briggs (2001)
Economic evaluation in health care -
(2004)
Grupos terapéuticos y principios activos de mayor consumo en el Sistema Nacional de Salud durante 2003Información Terapéutica del Sistema Nacional de Salud, 28
-
T. Andrews, C. Ballantyne, J. Hsia, Jeffrey Kramer (2001)
Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins.The American journal of medicine, 111 3
-
Peter Jones, M. Davidson, E. Stein, H. Bays, J. Mckenney, Elinor Miller, V. Cain, J. Blasetto (2003)
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial)American Journal of Cardiology, 92
-
G. Castańo, R. Menéndez, R. Más, A. Amor, F. Jl, González Rl, Magnolia Lezcay, E. Alvarez (2002)
Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus.International journal of clinical pharmacology research, 22 3-4
-
P. Plans-Rubió (2006)
Cost-Effectiveness Analysis of Cholesterol-Lowering Therapies in SpainAmerican Journal of Cardiovascular Drugs, 6
-
P. Rubió (2003)
Impacto sobre el Sistema Sanitario Catalán de la aplicación de las recomendaciones del segundo y tercer informes del National Cholesterol Education Program (ATP-II y ATP-III) sobre prevención y control de la hipercolesterolemia en adultosClínica e Investigación en Arteriosclerosis, 15
-
P. Serruys, D. Foley, G. Jackson, H. Bonnier, C. Macaya, M. Vrolix, A. Branzi, J. Shepherd, H. Suryapranata, P. Feyter, R. Melkert, G. Es, P. Pfister (1999)
A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial.European heart journal, 20 1
-
K. Schulman, B. Kinosian, T. Jacobson, H. Glick, M. Willian, H. Koffer, J. Eisenberg (1990)
Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management.JAMA, 264 23
-
J. Puig-Junoy (2007)
The impact of reference pricing interventions in the statin marketHealth Policy, 84
-
M. Law, N. Wald, A. Rudnicka (2003)
Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysisBMJ : British Medical Journal, 326
-
J. Zavoral, B. Haggerty, A. Winick, S. Bergmann (1995)
Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl coeezyme a reduefase inhibitorAmerican Journal of Cardiology, 76
-
Illingworth Dr, Tobert Ja (1994)
A review of clinical trials comparing HMG-CoA reductase inhibitors.Clinical Therapeutics, 16
-
J. Drazen, J. Jarcho, S. Morrissey, G. Curfman (2008)
Cholesterol lowering and ezetimibe.The New England journal of medicine, 358 14
-
J. Higgins, S. Thompson, J. Deeks, D. Altman (2003)
Measuring inconsistency in meta-analysesBMJ : British Medical Journal, 327
-
J. Daubresse (1993)
Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. The Simvastatin Pravastatin Study Group.The American journal of cardiology, 71 16
- Publisher
- Springer Journals
- Copyright
- Copyright © 2010 by Adis Data Information BV
- Subject
- Medicine & Public Health; Cardiology; Pharmacotherapy; Pharmacology/Toxicology
- ISSN
- 1175-3277
- eISSN
- 1179-187X
- DOI
- 10.2165/11539150-000000000-00000
- pmid
- 21090830
- Publisher site
- See Article on Publisher Site
Abstract
Am J Cardiovasc Drugs 2010; 10 (6): 369-382 ORIGINAL RESEARCH ARTICLE 1175-3277/10/0006-0369/$49.95/0 ª 2010 Adis Data Information BV. All rights reserved. The Cost Effectiveness of Statin Therapies in Spain in 2010, after the Introduction of Generics and Reference Prices Pedro Plans-Rubio´ Health Registries, General Directorate of Public Health, Health Department, Barcelona, Spain Abstract Background: HMG-CoA reductase inhibitors (statins) are the first-line drugs for use in the reduction of low-density lipoprotein cholesterol (LDL-C) levels and prevention of coronary heart disease (CHD) in patients with hypercholesterolemia. Generic statins could change the cost effectiveness of statin therapies in Spain, and more population groups could be included in the recommendations for reduction of cholesterol levels based on cost effectiveness. Objectives: The objectives of this study were: (i) to assess the cost effectiveness of available statins for the reduction of LDL-C levels in Spain in 2010, after the introduction of generics and reference prices; (ii) to assess the cost effectiveness of combination therapy using a statin plus cholestyramine or ezetimibe; and (iii) to estimate the mean cost per patient to achieve National Cholesterol Education Program (Adult Treatment Panel-III) therapeutic objectives. Methods: The following treatments were evaluated: rosuvastatin 5–20 mg/day; atorvastatin, simvastatin, and pravastatin 10–40
Journal
American Journal of Cardiovascular Drugs – Springer Journals
Published: Aug 20, 2012